Biogen announces presentation featured at EULAR 2016

Data from safety, comparable efficacy and immunogenicity studies on Biogen biologics, Benepali and Flixabi, were featured during the Annual European Congress of Rheumatology (EULAR 2016) this past week.

Both biosimilars had been approved by the European Commission (EC) this year and are currently commercialized in Europe through Biogen.

“Biologics have benefitted a large number of patients, effectively revolutionizing the treatment of rheumatic diseases,” SVP and Global Head of Biogen’s Biosimilars Business Unit Alpna Seth said. “Biosimilars can help more patients gain access and benefit from biologic therapies, while providing cost savings to health care systems and supporting future health care innovation. The data presented by our partners Samsung Bioepis at EULAR reinforce the comparable safety and efficacy of our anti-TNF biosimilars portfolio in patients living with chronic inflammatory conditions, including rheumatoid arthritis.”

Biogen stated that it was found that those who were given Benepali after taking the reference product, Enbrel, had reported no significant issues relating to immunogenicity. Those that were switched to Flixabi from Remicade reported no change in efficacy.

There were three presentations for Flixabi and one for Benepali that were made during the EULAR 2016 conference. The presentations were carried out by Samsung Bioepis, a joint venture between Biogen and Samsung BioLogics.